

**Remarks:**


Consideration of the foregoing amendments and following remarks is respectfully requested.

The amendments to the specification, except for the addition of the "Cross Reference to Related Applications" paragraph, were also made in U.S. Patent Application Serial No. 08/466,610. Applicant respectfully submits that the amendments to the specification introduced herein adds no new matter to the subject patent application.

The amendment cancels claim 3 which was found to be subject to no sustainable rejections by the Board of Patent Appeals and Interferences (Paper No. 31, page 10) in parent U.S. Patent Application Serial No. 08/466,610. Claim 3 will now be passed to issue in the parent application. No new matter has been added to the subject application by way of the addition of new claims 17 and 18. Claims 1-16 were the subject of the restriction requirement on 12/14/95 in U.S. Patent Application Serial No. 08/466,610 (Paper No. 4). Claims 5-16 were withdrawn from consideration and not further prosecuted. Claims 17 and 18 also were added during prosecution of the parent application (Amendment dated 6/13/96). Rejection of claims 1, 2, 4, 17 and 18 was sustained by the Board.

Applicant respectfully submits that the remaining claims in the present application are in condition for allowance. A favorable action thereon is, therefore, respectfully requested. Should the Examiner feel that any other point requires consideration or that the form of the claims can be improved, the Examiner is invited to contact the undersigned at the number listed below.

Respectfully submitted,

  
Grady J. Frenchick  
Reg. No. 29,018

File No. 011293-9028  
Michael Best & Friedrich LLP  
One South Pinckney Street  
P.O. Box 1806  
Madison, WI 53701-1806  
(608) 257-3501  
Q:\CLIENT\011293\9028\B0110136.DOC

**“Version with markings to show changes made”**

The changes made to the specification are shown by brackets [for deleted matter], and underlining for added matter.

In the specification, page 15, first full paragraph.

Electrotransport delivery device 10 includes a donor electrode assembly 8 and a counter electrode assembly 9. Electrode assemblies 8 and 9 are electrically connected to an electrical power source 27, which is typically one or more low voltage batteries, and an optional control circuit 19 [which is described in more detail hereinafter]. When the device 10 is placed on the skin or mucosal membrane of, e.g., a patient, the circuit between the electrodes is closed, and the power source begins to deliver current through the device and through the skin or mucosal membrane of the patient. The donor and counter electrode assemblies 8 and 9 normally include a strippable release liner (not shown in Figure 1) which is removed prior to application of electrode assemblies 8 and 9 to body surface 22.

In the specification, page 18, first full paragraph.

Human parathyroid hormone (h-PTH) is a pharmaceutical polypeptide used to treat osteoporosis. An example of an analog of h-PTH is one in which the glutamine residue at position 29 is replaced by histidine to increase the net charge by about +1 at pH 5. Replacement of the glutamine residue at position 29[.6] retains the approximate biological activity of the parent compound (SEQ ID NO:7).